Herpes zoster ophthalmicus

From HandWiki - Reading time: 7 min

Short description: Shingles in the human eye

Herpes zoster ophthalmicus
Other namesOphthalmic zoster
Herpes zoster ophthalmicus
SpecialtyOphthalmology
SymptomsRash of the forehead, swelling of the eyelid, pain and red eye
Complicationsvisual impairment, increased pressure within the eye, chronic pain, stroke
CausesReactivation of varicella zoster virus
Risk factorsPoor immune function, psychological stress, older age
Diagnostic methodBased on symptoms
PreventionHerpes zoster vaccine
MedicationAntiviral pills such as acyclovir, steroid eye drops
FrequencyUp to 125,000 per year (US)[1]

Herpes zoster ophthalmicus (HZO), also known as ophthalmic zoster, is shingles involving the eye or the surrounding area. Common signs include a rash of the forehead with swelling of the eyelid. There may also be eye pain and redness, inflammation of the conjunctiva, cornea or uvea, and sensitivity to light. Fever and tingling of the skin and allodynia near the eye may precede the rash. Complications may include visual impairment, increased pressure within the eye, chronic pain,[1][2][3] and stroke.[4]

The underlying mechanism involves a reactivation of the latent varicella zoster virus (VZV) within the trigeminal ganglion supplying the ophthalmic nerve (the first division of the trigeminal nerve). Diagnosis is generally based on signs and symptoms.[2] Alternatively, fluid collected from the rash may be analyzed for VZV DNA using real-time PCR. This test is rapid, easy to perform, and is highly sensitive and specific method for diagnosing this condition.[5]

Treatment is generally with antiviral pills such as acyclovir. Steroid eye drops and drops to dilate the pupil may also be used. The herpes zoster vaccine is recommended for prevention in those over the age of 50.[2] HZO is the second most common manifestation of shingles, the first being involvement of skin of the thorax. Shingles affects up to one half million people in the United States per year, of which 10% to 25% is HZO.[1][3]

Signs and symptoms

Skin

Trigeminal shingles with uveitis and keratitis
  • Viral prodrome
  • Preherpetic neuralgia
  • Rash, transitioning from papules to vesicles to pustules to scabs.
  • Hutchinson's sign: cutaneous involvement of the tip of the nose, indicating nasociliary nerve involvement. While a positive Hutchinson's sign increases the likelihood of ocular complications associated with HZO, its absence does not rule out ophthalmic involvement.[6]
  • Disseminated distribution in individuals with immunodeficiency.[7]

Cornea

Herpes zoster ophthalmicus as seen after fluorescence staining using cobalt blue light
  • Epithelial: punctate epithelial erosions and pseudodendrites: often have anterior stromal infiltrates. Onset 2 to 3 days after the onset of the rash, resolving within 2–3 weeks. Common.
  • Stromal:
    • Nummular keratitis: have anterior stromal granular deposits. Occurs within 10 days of onset of rash. Uncommon
    • Necrotising interstitial keratitis: Characterised by stromal infiltrates, corneal thinning and possibly perforation. Occurs between 3 months and several years after the onset of rash. Rare.
  • Disciform Keratitis (Disciform Endotheliitis): a disc of corneal oedema, folds in Descemet's membrane, mild inflammation evident within the anterior chamber and fine keratic precipitates. Chronic. Occurs between 3 months and several years after the onset of the rash. Uncommon.
  • Neurotrophic: corneal nerve damage causes a persistent epithelial defect, thinning and even perforation. The cornea becomes susceptible to bacterial and fungal keratitis. Chronic. Late onset. Uncommon.
  • Mucous plaques: linear grey elevations loosely adherent to the underlying diseased epithelium/stroma. Chronic. Onset between 3 months and several years after the onset of the rash.[7]

Uveal

Anterior uveitis develops in 40–50% of people with HZO within 2 weeks of the onset of the skin rashes. Typical HZO keratitis at least mild iritis, especially if Hutchinson's sign is positive for the presence of vesicles upon the tip of the nose.

Features:[8]

This non-granulomatous iridocyclitis is associated with:

HZO uveitis is associated with complications such as iris atrophy and secondary glaucoma are not uncommon. Complicated cataract may develop in the late stages of the disease.

Causes

Herpes Zoster or shingles is caused by the reactivation of latent human herpesvirus type 3 (Varicella Zoster virus), typically many years/decades later. A person can have this virus hidden away within their neurosensory ganglia after being infected initially (chickenpox) during childhood. However, HZO is specifically the reactivation of the latent virus within the first branch of the trigeminal nerve, called the ophthalmic branch of cranial nerve V. [9]

Risk Factors

Immunosuppression is the biggest factor for the reactivation of VZV and the development of herpes zoster. This can occur through acquired infection of HIV or through malignancy. Other risk factors besides immunosuppression that have been shown to have an increased risk of herpes zoster are family history, physical trauma, and increased age. Other less significant risk factors include female gender, psychological stress, and the presence of a variety of comorbidities like diabetes, rheumatoid arthritis, cardiovascular disease, renal disease, lupus, and inflammatory bowel disease.[10]

Mechanism

General distribution of the three divisions of the trigeminal nerve: ophthalmic, maxillary, and mandibular.

In the course of primary infection, which is normally acquired through respiratory droplets that invade the upper respiratory tract of the host.[11] Viral particles are believed to migrate retrograde from the site of skin infection along sensory neurons, eventually reaching the dorsal root ganglia. Once the primary infection is contained by the host immune system, the virus can enter a prolonged dormant state, most commonly in the spinal root or cranial nerve ganglia.[9] Reactivation of HZ leads to clinical manifestations localized withing the dermatome, or specific area of the human body, associated with the affected nerve.[11]

HZO is due to reactivation of VZV within the trigeminal ganglion, and the skin lesions that arise are usually limited to one side of the face. HZO more commonly erupts in the ophthalmic division of the trigeminal nerve compare to the other two divisions. [12] HZO follows the distribution of one or more branches of the ophthalmic divisions of the trigeminal nerve, typically the supraorbital nerve, the supratrochlear nerve, and the nasociliary nerve. Involvement of the nasociliary branch, which supplies the globe is associated with a higher risk of ocular complications.[13]

Viral replication leads to peripheral spread along sensory nerves and a localized inflammatory response, which manifests itself as pain with burning or tingling. When the virus reaches the skin, pustular lesions will develop. Involvement of the long ciliary nerves in HZO leads to potential inflammation of ocular structures like the cornea, sclera, conjunctiva, iris, retina, and optic nerve.[9]

Diagnosis

Prevention

Primary prevention of HZO is acquiring protection against primary infection with VZV. As a result, more than 90 percent of people not vaccinated against VZV will be infected in adolescence and become susceptible to developing HZO in the future.[14]

Treatment

Treatment is usually with antivirals such as acyclovir, valacyclovir, or famcyclovir by mouth.[2] There is uncertainty as to the difference in effect between these three antivirals.[15] Antiviral eye drops have not been found to be useful.[1] These medications work best if started within 3 days of the start of the rash.[3]

Cycloplegics prevent synechiae from forming.

Epidemiology

The annual incidence of Herpes Zoster is about 3.2 cases per 1000 people, with a marked increase in its frequency starting above the age of 60 and reaching the height of its incidence at age 90, about 9 cases per 1000 people.[16] Specifically, HZO occurs in about 10% of the estimated 1 million annual herpes zoster cases, with an incidence of 30.9 cases per 100,000 persons.[17]

References

  1. 1.0 1.1 1.2 1.3 "Herpetic Corneal Infections: Herpes Zoster Ophthalmicus". https://www.aao.org/focalpointssnippetdetail.aspx?id=8367b620-245c-4ebf-89e7-eca0c8d35aa3. 
  2. 2.0 2.1 2.2 2.3 "Herpes Zoster Ophthalmicus - Eye Disorders". https://www.merckmanuals.com/professional/eye-disorders/corneal-disorders/herpes-zoster-ophthalmicus. 
  3. 3.0 3.1 3.2 "Evaluation and management of herpes zoster ophthalmicus". American Family Physician 66 (9): 1723–30. November 2002. PMID 12449270. 
  4. "The relationship between herpes zoster and stroke". Current Neurology and Neuroscience Reports 15 (4): 16. April 2015. doi:10.1007/s11910-015-0534-4. PMID 25712420. 
  5. "Investigation of vesicular rashes for HSV and VZV by PCR". J. Med. Virol. 54 (3): 155–7. 1998. doi:10.1002/(SICI)1096-9071(199803)54:3<155::AID-JMV1>3.0.CO;2-4. PMID 9515761. 
  6. Butsch, Florian; Greger, Dania; Butsch, Christina; von Stebut, Esther (May 2017). "Prognostic value of Hutchinson's sign for ocular involvement in herpes zoster ophthalmicus: Correspondence" (in en). JDDG: Journal der Deutschen Dermatologischen Gesellschaft 15 (5): 563–564. doi:10.1111/ddg.13227. PMID 28422437. https://onlinelibrary.wiley.com/doi/10.1111/ddg.13227. Retrieved 2022-09-06. 
  7. 7.0 7.1 Denniston, Alastair K. O.; Murray, Philip I. (2009-06-11). Oxford Handbook of Ophthalmology. OUP Oxford. ISBN 978-0-19-955264-1. https://books.google.com/books?id=oFAFYRyFbr4C. Retrieved 2020-11-11. 
  8. Comprehensive Ophthalmology. Anshan. 2008. ISBN 978-1-905740-78-9. https://books.google.com/books?id=0fSyGAAACAAJ. Retrieved 2020-11-11. 
  9. 9.0 9.1 9.2 Vrcek, Ivan; Choudhury, Eileen; Durairaj, Vikram (2017-01-01). "Herpes Zoster Ophthalmicus: A Review for the Internist" (in English). The American Journal of Medicine 130 (1): 21–26. doi:10.1016/j.amjmed.2016.08.039. ISSN 0002-9343. PMID 27644149. https://www.amjmed.com/article/S0002-9343(16)30930-5/fulltext. 
  10. Marra, Fawziah; Parhar, Kamalpreet; Huang, Bill; Vadlamudi, Nirma (2020-01-01). "Risk Factors for Herpes Zoster Infection: A Meta-Analysis" (in en). Open Forum Infectious Diseases 7 (1). doi:10.1093/ofid/ofaa005. ISSN 2328-8957. PMID 32010734. PMC 6984676. https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofaa005/5698681. 
  11. 11.0 11.1 Zerboni, Leigh; Sen, Nandini; Oliver, Stefan L.; Arvin, Ann M. (March 2014). "Molecular mechanisms of varicella zoster virus pathogenesis" (in en). Nature Reviews Microbiology 12 (3): 197–210. doi:10.1038/nrmicro3215. ISSN 1740-1534. https://www.nature.com/articles/nrmicro3215. 
  12. Anderson, Erik; Fantus, Robert J.; Haddadin, Ramez I. (2017-02-01). "Diagnosis and management of herpes zoster ophthalmicus". Disease-a-Month. SI: Clinical Issues in Ophthalmology - Part I 63 (2): 38–44. doi:10.1016/j.disamonth.2016.09.004. ISSN 0011-5029. https://www.sciencedirect.com/science/article/pii/S0011502916300785. 
  13. Shaikh, Saad; Ta, Christopher N. (2002-11-01). "Evaluation and management of herpes zoster ophthalmicus". American Family Physician 66 (9): 1723–1730. ISSN 0002-838X. PMID 12449270. https://pubmed.ncbi.nlm.nih.gov/12449270. 
  14. Kovacevic, Jasmina; Samia, Arthur Mark; Shah, Ankit; Motaparthi, Kiran (July 2024). "Herpes zoster ophthalmicus" (in en). Clinics in Dermatology 42 (4): 355–359. doi:10.1016/j.clindermatol.2024.01.007. https://linkinghub.elsevier.com/retrieve/pii/S0738081X24000075. 
  15. Cochrane Eyes and Vision Group, ed (November 2016). "Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients". The Cochrane Database of Systematic Reviews 2016 (11). doi:10.1002/14651858.CD011503.pub2. PMID 27841441. 
  16. Insinga, Ralph P.; Itzler, Robbin F.; Pellissier, James M.; Saddier, Patricia; Nikas, Alexander A. (2005-08-01). "The incidence of herpes zoster in a United States administrative database" (in en). Journal of General Internal Medicine 20 (8): 748–753. doi:10.1111/j.1525-1497.2005.0150.x. ISSN 1525-1497. PMID 16050886. PMC 1490195. https://doi.org/10.1111/j.1525-1497.2005.0150.x. 
  17. Borkar, Durga S.; Tham, Vivien M.; Esterberg, Elizabeth; Ray, Kathryn J.; Vinoya, Aleli C.; Parker, John V.; Uchida, Aileen; Acharya, Nisha R. (2013-03-01). "Incidence of Herpes Zoster Ophthalmicus: Results from the Pacific Ocular Inflammation Study". Ophthalmology 120 (3): 451–456. doi:10.1016/j.ophtha.2012.09.007. ISSN 0161-6420. https://www.sciencedirect.com/science/article/pii/S0161642012008664. 
Classification
External resources

Template:Varicella zoster




Licensed under CC BY-SA 3.0 | Source: https://handwiki.org/wiki/Medicine:Herpes_zoster_ophthalmicus
4 views | Status: cached on February 11 2026 15:20:53
↧ Download this article as ZWI file
Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF